Updated: July 18, 2012 11:30 a.m.
OptiMedica Corp. is making waves and challenging the leaders in global eye care with its Catalys Precision Laser system for cataract surgery and CEO Mark Forchette isn’t shy about extolling his company’s potential.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Updated: July 18, 2012 11:30 a.m.
OptiMedica Corp. is making waves and challenging the leaders in global eye care with its Catalys Precision Laser system for cataract surgery and CEO Mark Forchette isn’t shy about extolling his company’s potential.
Veniti founder, president & CEO Sean Morris is on the march, looking to take over venous disease treatment with a suit of specialized devices that he hopes will knock out their more generic forebears.
Veniti, formed in 2009, specializes in devices for the venous anatomy, an arena often covered in a larger medical device company’s vascular devices business.
The seas are changing for medical device investment.
Venture capitalists are looking at their investment strategies since the 1990s and seeing a broken model focused on funding the familiar, placing safe bets in "incremental" devices that have since languished in a sort of med-tech limbo among other cloned startups with no exit strategy.
Jan Keltjens is betting Endosense and its TactiCath technology can compete with 1 of the largest players in cardiac ablation: Johnson & Johnson‘s (NYSE:JNJ) BioSense Webster division.
When the medical device tax is successfully repealed this week by the House of Representatives, which is pretty much guaranteed given that the bill has more than enough cosponsors to pass (240 at last tally), it won’t just be an important, albeit symbolic, victory for the med-tech industry.
When Novocure won FDA approval for its Tumor Targeting Field cancer therapy system, the company introduced the oncology world to an entire new modality for treatment.
Cancer patients today are most famliar with surgery, radiation and chemotherapy as thearpy optoins, but certain patients can also opt for Novocure’s non-invasive electromagnetic therapy, which promises to stop cancer cells in their tracks without adding a new suite of side effects.
Click here to listen to the podcast
"In the U.S., for Class III heart failure there are about 1.5 million patients," Sunshine Heart CEO David Rosa told MassDevice.com in an exclusive podcast interview. "That’s about 7 times the Class IV market, which is traditionally where LVADs participate."
MassDevice.com: I’m interested in your thoughts on the increased pressure to take costs out of the system as well as to improve outcomes. Is that a damper on innovation?